This program is investigating the utility of plasma microRNA signatures as minimally invasive biomarkers of glioblastoma, in collaboration with the University of Pennsylvania. Glioblastoma carries a median survival of fewer than 15 months after diagnosis, and its detection and monitoring rely on imaging and invasive biopsy. A blood-based marker could support earlier detection and monitoring.